[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"notifications-list":3,"$f13tewe8jdwriz":5},{"data":4},[],{"data":6,"error":10},{"id":7,"documentId":8,"slug":9,"name":9,"proprietary_name":10,"non_proprietary_name":10,"is_proprietary":10,"active_ingredient":10,"administration_route":10,"available_strength":10,"dosage_form":10,"dose_schedule":10,"drug_unit":10,"is_available_generically":10,"mechanism_of_action":10,"overdosage":10,"warning":10,"species":11,"citations":12,"dose_schedules":27,"available_strengths":39,"label_statements":44,"drug_classes":71,"specialties":77,"medical_conditions":78,"animal_species":79},1881,"g5ldwm4a7uc9iw169r0e89zy","trilostane",null,[],[13,19,23],{"source":14,"licence":15,"source_url":16,"harvested_by":17,"retrieved_at":18},"EMA centrally authorised medicines","EMA reuse with attribution","https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fdocuments\u002Freport\u002Fmedicines-output-medicines-report_en.xlsx","load-reference-corpus.cjs","2026-09-07",{"source":20,"licence":21,"source_url":22,"harvested_by":17,"retrieved_at":18},"FDA Green Book","US public domain","https:\u002F\u002Fanimaldrugsatfda.fda.gov\u002Fadafda\u002Fapp\u002Fsearch\u002Fpublic\u002FingredientsInformationExcel\u002FSection2ActiveIngredients",{"source":24,"licence":25,"source_url":26,"harvested_by":17,"retrieved_at":18},"UK VMD PID","OGL v3.0","https:\u002F\u002Fwww.vmd.defra.gov.uk\u002Fproductinformationdatabase\u002Fdownloads\u002Fvmd_productinformationdatabase.xlsx",[28,34],{"id":29,"dose_text":30,"species":31,"administration_route":32,"limitation":10,"source_label":33},13861,"The starting dose for the treatment of hyperadrenocorticism in dogs is 1.0 to 3.0 mg\u002Flb (2.2 to 6.7 mg\u002Fkg) once a day based on body weight and capsule size. Capsules should be administered with food.","Dogs","Oral","VETORYL® CAPSULES",{"id":35,"dose_text":36,"species":10,"administration_route":37,"limitation":10,"source_label":38},13862,"Always provide the Client Information Sheet with prescription (see\nINFORMATION FOR DOG OWNERS\n).","ORAL","VETORYL® CAPSULES (trilostane)",[40],{"id":41,"strength_text":42,"dosage_form":43,"proprietary_name":33,"species":31,"source_label":33},12039,"Each capsule contains 5, 10, 20, 30, 60, or 120 mg trilostane.","Capsule",[45,49,52,56,60,63,67],{"id":46,"kind":47,"statement":48,"species":31,"limitation":10,"source_label":33},20402,"indication","For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism in dogs.",{"id":50,"kind":47,"statement":51,"species":10,"limitation":10,"source_label":38},20403,"VETORYL Capsules are indicated for the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism in dogs.",{"id":53,"kind":54,"statement":55,"species":10,"limitation":10,"source_label":38},20404,"contraindication","The use of VETORYL Capsules is contraindicated in dogs that have demonstrated hypersensitivity to trilostane.\nDo not use VETORYL Capsules in animals with primary hepatic disease or renal insufficiency (See\nWARNINGS\nand\nPRECAUTIONS\n).\nDo not use in pregnant dogs. Studies conducted with trilostane in laboratory animals have shown teratogenic effects and early pregnancy loss.",{"id":57,"kind":58,"statement":59,"species":10,"limitation":10,"source_label":38},20405,"warning","Hypoadrenocorticism can develop at any dose of VETORYL Capsules. In some cases, it may take months for adrenal function to return and some dogs never regain adequate adrenal function.\nAll dogs should undergo a thorough history and physical examination before initiation of therapy with VETORYL Capsules. Other conditions, such as primary hepatic and\u002For renal disease should be considered when the patient is exhibiting signs of illness in addition to signs of hyperadrenocorticism (e.g. vomiting, diarrhea, poor\u002Freduced appetite, weight loss, and lethargy). Appropriate laboratory tests to establish hematological and serum biochemical baseline data prior to, and periodically during, administration of VETORYL Capsules should be considered.\nOwners should be advised to discontinue therapy immediately and contact their veterinarian if signs of potential drug toxicity are observed (see INFORMATION FOR DOG OWNERS, DOSAGE AND ADMINISTRATION, PRECAUTIONS, ADVERSE REACTIONS, ANIMAL SAFETY and POST-APPROVAL EXPERIENCE).\nIn case of overdosage, symptomatic treatment of hypoadrenocorticism with corticosteroids, mineralocorticoids and intravenous fluids may be required.\nAngiotensin converting enzyme (ACE) inhibitors should be used with caution with VETORYL Capsules, as both drugs have aldosterone-lowering effects which may be additive, impairing the patient's ability to maintain normal electrolytes, blood volume and renal perfusion. Potassium sparing diuretics (e.g. spironolactone) should not be used with VETORYL Capsules as both drugs have the potential to inhibit aldosterone, increasing the likelihood of hyperkalemia.",{"id":61,"kind":58,"statement":62,"species":10,"limitation":10,"source_label":38},20406,"Keep out of reach of children. Not for human use.\nWash hands after use. Do not empty capsule contents and do not attempt to divide the capsules. Do not handle the capsules if pregnant or if trying to conceive. Trilostane is associated with teratogenic effects and early pregnancy loss in laboratory animals. In the event of accidental ingestion\u002Foverdose, seek medical advice immediately and take the labeled container with you.",{"id":64,"kind":65,"statement":66,"species":10,"limitation":10,"source_label":38},20407,"adverse_reaction","The most common adverse reactions reported are poor\u002Freduced appetite, vomiting, lethargy\u002Fdullness, diarrhea, and weakness. Occasionally, more serious reactions, including severe depression, hemorrhagic diarrhea, collapse, hypoadrenocortical crisis or adrenal necrosis\u002Frupture may occur, and may result in death.\nIn a US field study with 107 dogs, adrenal necrosis\u002Frupture (two dogs) and hypoadrenocorticism (two dogs) were the most severe adverse reactions in the study. One dog died suddenly of adrenal necrosis, approximately one week after starting trilostane therapy. One dog developed an adrenal rupture, believed to be secondary to adrenal necrosis, approximately six weeks after starting trilostane therapy. This dog responded to trilostane discontinuation and supportive care.\nTwo dogs developed hypoadrenocorticism during the study. These two dogs had clinical signs consistent with hypoadrenocorticism (lethargy, anorexia, collapse) and post-ACTH cortisol levels ≤ 0.3 μg\u002FdL. Both dogs responded to trilostane discontinuation and supportive care, and one dog required continued treatment for hypoadrenocorticism (glucocorticoids and mineralocorticoids) after the acute presentation.\nAdditional adverse reactions were observed in 93 dogs. The most common of these included diarrhea (31 dogs), lethargy (30 dogs), inappetence\u002Fanorexia (27 dogs), vomiting (28 dogs), musculoskeletal signs (lameness, worsening of degenerative joint disease) (25 dogs), urinary tract infection (UTI)\u002Fhematuria (17 dogs), shaking\u002Fshivering (10 dogs), otitis externa (8 dogs), respiratory signs (coughing, congestion) (7 dogs), and skin\u002Fcoat abnormality (seborrhea, pruritus) (8 dogs).\nFive dogs died or were euthanized during the study (one dog secondary to adrenal necrosis, discussed above, two dogs due to progression of pre-existing congestive heart failure, one dog due to progressive central nervous system signs, and one dog due to cognitive decline leading to inappropriate elimination). In addition to the two dogs with adrenal necrosis\u002Frupture and the two dogs with hypoadrenocorticism, an additional four dogs were removed from the study as a result of possible trilostane-related adverse reactions, including collapse, lethargy, inappetence, and trembling. Complete blood counts conducted pre- and post-treatment revealed a statistically significant (p \u003C0.005) reduction in red cell variables (HCT, HGB, and RBC), but the mean values remained within the normal range. Additionally, approximately 10% of the dogs had elevated BUN values (≥ 40 mg\u002FdL) in the absence of concurrent creatinine elevations. In general, these dogs were clinically normal at the time of the elevated BUN.\nIn a long term follow-up study of dogs in the US effectiveness study, the adverse reactions were similar to the short term study. Vomiting, diarrhea and general gastrointestinal signs were most commonly observed. Lethargy, inappetence\u002Fanorexia, heart murmur or cardiopulmonary signs, inappropriate urination\u002Fincontinence, urinary tract infections or genitourinary disease, and neurological signs were reported. Included in the US follow-up study were 14 deaths, three of which were possibly related to trilostane. Eleven dogs died or were euthanized during the study for a variety of conditions considered to be unrelated to or to have an unknown relationship with administration of trilostane.\nIn two UK field studies with 75 dogs, the most common adverse reactions seen were vomiting, lethargy, diarrhea\u002Floose stools, and anorexia. Other adverse reactions included: nocturia, corneal ulcer, cough, persistent estrus, vaginal discharge and vulvar swelling in a spayed female, hypoadrenocorticism, electrolyte imbalance (elevated potassium with or without decreased sodium), collapse and seizure, shaking, muscle tremors, constipation, scratching, weight gain, and weight loss. One dog died of congestive heart failure and another died of pulmonary thromboembolism. Three dogs were euthanized during the study. Two dogs had renal failure and another had worsening arthritis and deterioration of appetite.\nIn a long term follow-up of dogs included in the UK field studies, the following adverse reactions were seen: hypoadrenocortical episode (including syncope, tremor, weakness, and vomiting), hypoadrenocortical crisis or renal failure (including azotemia, vomiting, dehydration, and collapse), chronic intermittent vaginal discharge, hemorrhagic diarrhea, occasional vomiting, and distal limb edema. Signs of hypoadrenocorticism were usually reversible after withdrawal of the drug, but may be permanent. One dog discontinued VETORYL Capsules and continued to have hypoadrenocorticism when evaluated a year later. Included in the follow-up were reports of deaths, at least 5 of which were possibly related to use of VETORYL Capsules. These included dogs that died or were euthanized because of renal failure, hypoadrenocortical crisis, hemorrhagic diarrhea, and hemorrhagic gastroenteritis.",{"id":68,"kind":69,"statement":70,"species":10,"limitation":10,"source_label":38},20408,"mechanism_of_action","Trilostane absorption is enhanced by administration with food. In healthy dogs, maximal plasma levels of trilostane occur within 1.5 hours, returning to baseline levels within twelve hours, although large inter-dog variation occurs. There is no accumulation of trilostane or its metabolites over time.",[72],{"id":73,"documentId":74,"slug":75,"name":76},973,"4lfu4sd1xmeutyq5frf1pqr5","antiadrenal-preparations","Antiadrenal preparations",[],[],[]]